Publications
Detailed Information
Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Mungyo | - |
dc.contributor.author | Kang, Mikyung | - |
dc.contributor.author | Kim, Byung-Seok | - |
dc.contributor.author | Hong, Jihye | - |
dc.contributor.author | Kim, Cheesue | - |
dc.contributor.author | Koh, Choong-Hyun | - |
dc.contributor.author | Choi, Garam | - |
dc.contributor.author | Chung, Yeonseok | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.date.accessioned | 2023-04-19T00:20:36Z | - |
dc.date.available | 2023-04-19T00:20:36Z | - |
dc.date.created | 2022-03-21 | - |
dc.date.issued | 2022-03-01 | - |
dc.identifier.citation | Advanced Materials, Vol.34 No.9, p. 2106516 | - |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.uri | https://hdl.handle.net/10371/190188 | - |
dc.description.abstract | Despite the clinically proven efficacies of immune checkpoint blockades, including anti-cytotoxic T lymphocyte-associated protein 4 antibody (alpha CTLA-4), the low response rate and immune-related adverse events (irAEs) in cancer patients represent major drawbacks of the therapy. These drawbacks of alpha CTLA-4 therapy are mainly due to the suboptimal activation of tumor-specific cytotoxic T lymphocytes (CTLs) and the systemic nonspecific activation of T cells. To overcome such drawbacks, alpha CTLA-4 is delivered by dendritic cell-derived nanovesicles presenting tumor antigens (DCNV-TAs) that exclusively interact with tumor-specific T cells, leading to selective activation of tumor-specific CTLs. Compared to conventional alpha CTLA-4 therapy, treatment with alpha CTLA-4-conjugated DCNV-TAs significantly inhibits tumor growth and reduces irAEs in syngeneic tumor-bearing mice. This study demonstrates that the spatiotemporal presentation of both alpha CTLA-4 and tumor antigens enables selective activation of tumor-specific T cells and potentiates the antitumor efficacy of alpha CTLA-4 without inducing systemic irAEs. | - |
dc.language | 영어 | - |
dc.publisher | WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim | - |
dc.title | Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/adma.202106516 | - |
dc.citation.journaltitle | Advanced Materials | - |
dc.identifier.wosid | 000746512800001 | - |
dc.identifier.scopusid | 2-s2.0-85123491401 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 2106516 | - |
dc.citation.volume | 34 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Chung, Yeonseok | - |
dc.contributor.affiliatedAuthor | Kim, Byung-Soo | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL-DERIVED EXOSOMES | - |
dc.subject.keywordPlus | REGULATORY T-CELLS | - |
dc.subject.keywordPlus | TUMOR-ANTIGENS | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | CTLA-4 | - |
dc.subject.keywordPlus | VACCINE | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | IPILIMUMAB | - |
dc.subject.keywordPlus | INHIBITORS | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | dendritic cells | - |
dc.subject.keywordAuthor | immune checkpoint inhibitors | - |
dc.subject.keywordAuthor | immune-related adverse events | - |
dc.subject.keywordAuthor | nanovesicles | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.